Form 4: Imunon Director Acquires Shares for Board Fees

Imunon, Inc. reports a Form 4 filing detailing the acquisition of common stock by Director Frederick J. Fritz as compensation for board services.

Summary

• Frederick J. Fritz, a Director at Imunon, Inc., acquired 10,330 shares of common stock on May 22, 2026.
• These shares were granted in lieu of cash for a portion of his board fees.
• The acquisition price was $2.20 per share, totaling $22,726.
• Following this transaction, Mr. Fritz beneficially owns 14,097 shares of common stock.
• The filing also notes a 15% stock dividend paid on August 21, 2025, which adjusted previously reported share amounts.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily details a routine director compensation transaction rather than providing significant new financial or strategic information about the company.

Positives

• Director compensation is being partially settled with stock, aligning director interests with shareholders.
• The acquisition of shares by a director can signal confidence in the company's future prospects.

Negatives

• The filing does not provide details on the company's financial performance or operational status, making it difficult to assess the broader implications of this transaction.

Risks

• The company's financial health and operational performance are not detailed in this filing, which could pose risks to the value of the acquired shares.
• The stock dividend adjustment mentioned could indicate past dilution or restructuring, the details of which are not provided.

Future Outlook

No specific forward-looking statements or guidance are provided in this Form 4 filing.

Management Comments

• Stock granted in lieu of cash for portion of board fees.
• As a result of the stock dividend, the shares of Issuer Common Stock have been adjusted accordingly versus any amounts previously reported by the Reporting Person.

Industry Context

StockSavvy.ai notes that the use of stock grants for director compensation is a common practice in the biotechnology and pharmaceutical sectors, aiming to align executive interests with long-term shareholder value. However, without further context on Imunon's specific financial performance or clinical trial progress, it's difficult to assess the broader strategic implications of this compensation method.

Related Party Transactions

• The acquisition of shares by Director Frederick J. Fritz for board fees constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The issuance of stock for board fees can dilute existing share ownership, but also aligns director interests with shareholder value creation.
• Employees: No direct impact mentioned.
• Creditors: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Customers: No direct impact mentioned.

Next Steps

• No specific next steps are outlined in this filing.

Key Dates

Keywords

Imunon Inc, IMNN, Form 4, Insider Transaction, Director Compensation, Stock Acquisition, Beneficial Ownership, SEC Filing